Current status of vaccine development for tularemia preparedness
- PMID: 23596588
- PMCID: PMC3623498
- DOI: 10.7774/cevr.2013.2.1.34
Current status of vaccine development for tularemia preparedness
Abstract
Tularemia is a high-risk infectious disease caused by Gram-negative bacterium Francisella tularensis. Due to its high fatality at very low colony-forming units (less than 10), F. tularensis is considered as a powerful potential bioterrorism agent. Vaccine could be the most efficient way to prevent the citizen from infection of F. tularensis when the bioterrorism happens, but officially approved vaccine with both efficacy and safety is not developed yet. Research for the development of tularemia vaccine has been focusing on the live attenuated vaccine strain (LVS) for long history, still there are no LVS confirmed for the safety which should be an essential factor for general vaccination program. Furthermore the LVS did not show protection efficacy against high-risk subspecies tularensis (type A) as high as the level against subspecies holarctica (type B) in human. Though the subunit or recombinant vaccine candidates have been considered for better safety, any results did not show better prevention efficacy than the LVS candidate against F. tularensis infection. Currently there are some more trials to develop vaccine using mutant strains or nonpathogenic F. novicida strain, but it did not reveal effective candidates overwhelming the LVS either. Difference in the protection efficacy of LVS against type A strain in human and the low level protection of many subunit or recombinant vaccine candidates lead the scientists to consider the live vaccine development using type A strain could be ultimate answer for the tularemia vaccine development.
Keywords: Bioterrorism agent; Fracisella tularensis; Preparedness; Tularemia; Vaccines.
Conflict of interest statement
No potential conflict of interest relevant to this article was reported.
Figures


Similar articles
-
Live Attenuated Tularemia Vaccines for Protection Against Respiratory Challenge With Virulent F. tularensis subsp. tularensis.Front Cell Infect Microbiol. 2018 May 15;8:154. doi: 10.3389/fcimb.2018.00154. eCollection 2018. Front Cell Infect Microbiol. 2018. PMID: 29868510 Free PMC article. Review.
-
Perforin- and granzyme-mediated cytotoxic effector functions are essential for protection against Francisella tularensis following vaccination by the defined F. tularensis subsp. novicida ΔfopC vaccine strain.Infect Immun. 2012 Jun;80(6):2177-85. doi: 10.1128/IAI.00036-12. Epub 2012 Apr 9. Infect Immun. 2012. PMID: 22493083 Free PMC article.
-
Francisella tularensis Live Vaccine Strain deficient in capB and overexpressing the fusion protein of IglA, IglB, and IglC from the bfr promoter induces improved protection against F. tularensis respiratory challenge.Vaccine. 2016 Sep 22;34(41):4969-4978. doi: 10.1016/j.vaccine.2016.08.041. Epub 2016 Aug 28. Vaccine. 2016. PMID: 27577555 Free PMC article.
-
A heterologous prime-boost vaccination strategy comprising the Francisella tularensis live vaccine strain capB mutant and recombinant attenuated Listeria monocytogenes expressing F. tularensis IglC induces potent protective immunity in mice against virulent F. tularensis aerosol challenge.Infect Immun. 2013 May;81(5):1550-61. doi: 10.1128/IAI.01013-12. Epub 2013 Feb 25. Infect Immun. 2013. PMID: 23439306 Free PMC article.
-
Vaccination strategies for Francisella tularensis.Adv Drug Deliv Rev. 2005 Jun 17;57(9):1403-14. doi: 10.1016/j.addr.2005.01.030. Adv Drug Deliv Rev. 2005. PMID: 15919131 Review.
Cited by
-
Differential Immune Response Following Intranasal and Intradermal Infection with Francisella tularensis: Implications for Vaccine Development.Microorganisms. 2021 Apr 30;9(5):973. doi: 10.3390/microorganisms9050973. Microorganisms. 2021. PMID: 33946283 Free PMC article. Review.
-
Development of dual reporter imaging system for Francisella tularensis to monitor the spatio-temporal pathogenesis and vaccine efficacy.Clin Exp Vaccine Res. 2018 Jul;7(2):129-138. doi: 10.7774/cevr.2018.7.2.129. Epub 2018 Jul 31. Clin Exp Vaccine Res. 2018. PMID: 30112352 Free PMC article.
-
Development of Effective Medical Countermeasures Against the Main Biowarfare Agents: The Importance of Antibodies.Microorganisms. 2024 Dec 18;12(12):2622. doi: 10.3390/microorganisms12122622. Microorganisms. 2024. PMID: 39770824 Free PMC article. Review.
-
Intranasal administration of a two-dose adjuvanted multi-antigen TMV-subunit conjugate vaccine fully protects mice against Francisella tularensis LVS challenge.PLoS One. 2018 Apr 23;13(4):e0194614. doi: 10.1371/journal.pone.0194614. eCollection 2018. PLoS One. 2018. PMID: 29684046 Free PMC article.
-
The immune response to Francisella tularensis.Front Microbiol. 2025 Apr 25;16:1549343. doi: 10.3389/fmicb.2025.1549343. eCollection 2025. Front Microbiol. 2025. PMID: 40351308 Free PMC article. Review.
References
-
- Saslaw S, Eigelsbach HT, Prior JA, Wilson HE, Carhart S. Tularemia vaccine study. II. Respiratory challenge. Arch Intern Med. 1961;107:702–714. - PubMed
-
- Saslaw S, Eigelsbach HT, Wilson HE, Prior JA, Carhart S. Tularemia vaccine study. I. Intracutaneous challenge. Arch Intern Med. 1961;107:689–701. - PubMed
-
- Dennis DT, Inglesby TV, Henderson DA, et al. Tularemia as a biological weapon: medical and public health management. JAMA. 2001;285:2763–2773. - PubMed
-
- Keim P, Johansson A, Wagner DM. Molecular epidemiology, evolution, and ecology of Francisella. Ann N Y Acad Sci. 2007;1105:30–66. - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources